HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir (STO:MVIR-B): Interim period, January-September 2012
Net turnover totalled SEK 399.5 million (SEK 566.8 m), of which non-recurrent payments comprised SEK 0.0 million (SEK 401.2 million), sales of pharmaceuticals, SEK 120.6 million (SEK 63.7 m), and sales via parallel imports, SEK 277.7 million (SEK 101.2 m).
